FDA Reconsidering Drug Safety Reporting Methods
home > blogdigger
Probably the weakest link in the conventional health care paradigm that's pushed many people to consider alternative treatments, especially over the past year: The FDA's means of monitoring drug safety, with the saga of controversial anti-inflammatories Vioxx, Celebrex and Bextra still fresh on the minds of many patients and legislators. Acknowledging flaws in its Adverse Event Reporting System (AERS), the FDA begins a two-day hearing this morning to discuss improvements. Although top officials ... (more)
- link to FDA Reconsidering Drug Safety Reporting Methods -
Last update: 05/26/2005